O'Neil long-acting naltrexone implant

The O'Neil Long-Acting Naltrexone Implant (OLANI) is a biodegradable, subcutaneous implant developed by the Australian pharmaceutical company Go Medical Industries, in collaboration with Dr. George O'Neil. The active ingredient is naltrexone, a small-molecule opioid receptor antagonist that blocks opioid receptors in the brain, reducing or eliminating opioid effects and cravings to prevent relapse. The implant is inserted subcutaneously into the abdominal tissue and is designed to slowly release a controlled, constant dose of naltrexone for up to 6 to 18 months before biodegrading and being fully absorbed by the body. It is intended to treat opioid dependence (opioid use disorder) and alcohol dependence. The OLANI has been evaluated in Phase 2 and Phase 3 clinical trials, including a Phase 3 single-group Australian trial assessing safety and efficacy in people with substance dependence over 12 months post-implantation. The FDA granted an Investigational New Drug (IND) application for the Naltrexone Subcutaneous Implant in 2018.

Other names

OLANIO'Neil Long-Acting Naltrexone ImplantO'Neil Long Acting Naltrexone ImplantNaltrexone Subcutaneous Implant